Amgen Inc. Stock Performance
Amgen Inc. shares closed at $402.60, reflecting a daily decline of 2.50% per SID market data. The stock currently trades below its 50-day moving average of $410.55, suggesting near-term softness, while remaining well above its 200-day moving average of $370.94, which indicates a sustained longer-term uptrend. Over the trailing twelve months, AMGN has gained 21.49%, outpacing many large-cap healthcare peers. However, the one-month return of negative 7.92% signals recent selling pressure that has partially offset a solid three-month gain of 9.41%. The 14-day relative strength index stands at 67.1, approaching but not yet reaching overbought territory. Amgen's beta of 0.472, according to Massive/Polygon data, reflects significantly lower volatility relative to the broader market. Average daily trading volume registers at approximately 2.89 million shares, and the company maintains a market capitalization of approximately $209.2 billion.
Amgen Inc. Valuation Analysis
Amgen Inc. trades at a price-to-earnings ratio of 27.13, per SID market data, which represents a premium relative to the broader healthcare sector's historical averages. The company's PEG ratio stands at 2.72, suggesting that the current earnings multiple exceeds the implied growth rate and that shares may be fully valued on a growth-adjusted basis. The price-to-book ratio of 24.16 reflects the asset-light, intellectual-property-intensive nature of Amgen's biopharmaceutical business model, consistent with industry norms for large-cap biotech firms. According to SEC filings, Amgen offers a dividend yield of approximately 2.49%, providing income-oriented investors with a meaningful yield supported by the company's strong free cash flow generation. At a market capitalization of $209.2 billion, Amgen ranks among the largest biotechnology companies globally. These valuation metrics collectively position the stock at a moderate premium within its peer group.
Smart Money Activity for AMGN
Amgen Inc. registers a composite smart money score of 48 out of 100, signaling a neutral overall stance among sophisticated market participants, per SID market data. Institutional ownership sentiment scores a perfect 25 out of 25, indicating robust conviction from major fund managers and pension allocators. In contrast, the insider trading component scores just 8.6 out of 25 despite a modestly constructive pattern. According to SEC Form 4 filings, there have been 15 insider transactions over the past 90 days, comprising 9 purchases and 6 sales, reflecting a net buying bias among company executives and directors. Dark pool activity scores 8.5 out of 25, suggesting limited off-exchange accumulation by institutional participants in recent weeks. Congressional trading activity registers at 5.9 out of 25 based on 13F institutional filings and public disclosure records. The divergence between strong institutional support and tepid insider and dark pool signals creates a mixed overall smart money reading for AMGN.
Amgen Inc. Earnings Outlook
Amgen Inc. has delivered three consecutive quarters of earnings beats, according to company earnings reports. In the most recent reported quarter, the company posted earnings per share of $6.29 against analyst estimates of $5.60, representing a positive surprise of $0.69 or approximately 12.3%. The prior quarter saw EPS of $5.15 versus estimates of $4.76, a beat of $0.39, while the quarter before that delivered $5.29 against a $4.75 consensus, exceeding expectations by $0.54. This consistent pattern of outperformance underscores management's ability to execute above Wall Street projections. Looking ahead, analyst estimates project EPS of $5.76 for the upcoming quarter, with results expected on November 3, 2026. The trajectory of rising earnings estimates and sequential beats suggests underlying business momentum across Amgen's diversified biopharmaceutical portfolio, including key growth drivers in its oncology and inflammation franchises.
Wall Street Analyst Ratings for AMGN
Recent Wall Street analyst activity for Amgen Inc. reflects a mixed sentiment shift, per SID consensus data. On September 29, 2026, Scotiabank maintained its Sector Outperform rating, reaffirming a constructive long-term thesis on the stock. However, two notable downgrades emerged on September 8: HSBC downgraded AMGN from Buy to Hold, while BMO Capital moved from Outperform to Market Perform, according to Wall Street analyst reports. These downgrades suggest that some analysts view the recent price appreciation as having captured much of the near-term upside. Cantor Fitzgerald reiterated its Neutral stance on the same date, and Wells Fargo maintained its Equal-Weight rating on September 4. The clustering of three neutral-leaning actions within a single week stands in contrast to Scotiabank's more bullish positioning. With the stock trading at a P/E of 27.13 and having gained 21.49% over the past year, the cautious analyst tone may reflect valuation concerns following the sustained rally.
